Clinical review report : Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Injections, Hypodermic.

Outcome assessment (Medical care).

Physical Description:

1 online resource

Edition:

Final edition.

Place of Publication:

Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2020.

Summary:

The objective of this review is to perform a systematic review of the beneficial and harmful effects of Ixekizumab (solution for subcutaneous injection, 80 mg/1.0 mL) for the treatment of adult patients with active Ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy.

Contents:

Abbreviations

Executive Summary

Introduction

Stakeholder Engagement

Clinical Evidence

Conclusions

Disease Background

Standards of Therapy

Drug

Patient Group Input

Clinician Input

Systematic Review (Pivotal and Protocol Selected Studies)

Findings from the Literature

Results

Indirect Evidence

Other Relevant Studies

Discussion

Summary of Available Evidence

Interpretation of Results

Appendix 1. Literature Search Strategy

Appendix 2. Excluded Studies

Appendix 3. Detailed Outcome Data

Appendix 4. Description and Appraisal of Outcome Measures

References.

Notes:

Description based on publisher supplied metadata and other sources.